Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Verve Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023 Well-capitalized with Cash Runway into 2026"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of 2024 Well-capitalized with $508.7 Million Supporting Runway into the Second Half of 2025"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
03/02/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporting Runway into the Second Half of 2025"
02/23/2023 3 Nickerson Joan (Chief Administrative Officer) has filed a Form 3 on Verve Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2023 SC 13G ARK Investment Management LLC reports a 7.1% stake in Verve Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 11.2% stake in VERVE THERAPEUTICS INC
02/09/2023 SC 13G VANGUARD GROUP INC reports a 6.2% stake in Verve Therapeutics Inc.
02/07/2023 SC 13G STATE STREET CORP reports a 7.3% stake in INITIAL FILING VERVE THERAPEUTICS INC
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/16/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/05/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/02/2022 4 Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Sold 865 shares @ $22.95, valued at $19.9k
12/01/2022 4 Dorval Allison (CFO) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Sold 554 shares @ $22.1, valued at $12.2k
Exercised 1,875 restricted stock units @ $0
11/08/2022 4 Yeshwant Krishna (10% Owner) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Disposed of 48,583 shares @ $0
Sold 47,690 shares @ $31.118, valued at $1.5M
Sold 650 shares @ $31.9905, valued at $20.8k
Sold 243 shares @ $32.9, valued at $8k
11/08/2022 4 GV 2017 GP, L.L.C. (Member of 10% Group) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Disposed of 48,583 shares @ $0
Sold 47,690 shares @ $31.118, valued at $1.5M
Sold 651 shares @ $31.9905, valued at $20.8k
Sold 242 shares @ $32.9, valued at $8k
Sold 47,690 shares @ $31.118, valued at $1.5M
Sold 650 shares @ $31.9905, valued at $20.8k
Sold 243 shares @ $32.9, valued at $8k
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Dose Level in New Zealand and U.K. Well-capitalized with $550.7 Million Supporting Runway into Second Half of 2025"
11/04/2022 4 Yeshwant Krishna (10% Owner) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Disposed of 28,651 shares @ $0
Sold 9,350 shares @ $34.7754, valued at $325.1k
Sold 10,372 shares @ $36.2786, valued at $376.3k
Sold 8,930 shares @ $36.775, valued at $328.4k
Disposed of 49,569 shares @ $0
Sold 22,279 shares @ $32.3155, valued at $720k
Sold 25,534 shares @ $33.1384, valued at $846.2k
Sold 1,755 shares @ $33.8373, valued at $59.4k
11/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/05/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/27/2022 4 Bellinger Andrew (CSO & CMO) has filed a Form 4 on Verve Therapeutics, Inc.
Txns: Sold 6,632 shares @ $34.666, valued at $229.9k
Sold 13,368 shares @ $35.5927, valued at $475.8k
Sold 36,798 shares @ $35.3091, valued at $1.3M
Sold 3,202 shares @ $36.0336, valued at $115.4k
Exercised 40,000 options to buy @ $1.48, valued at $59.2k
Exercised 20,000 options to buy @ $1.48, valued at $29.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy